Unione Europea - italiano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus vcp1338 - immunostimolanti, antineoplastici e immunomodulatori agenti, immunostimolanti, - gatti - l'immunoterapia per essere utilizzato in associazione con la chirurgia e la radioterapia nei gatti con fibrosarcoma (2-5 cm di diametro), senza metastasi o di coinvolgimento linfonodale, per ridurre il rischio di recidiva e di aumentare il tempo alla recidiva (recidiva locale o metastasi).

Unione Europea - italiano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unione Europea - italiano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Italia - italiano - Ecolab

ecolab deutschland gmbh -

Italia - italiano - Ministero della Salute

le vet beheer b.v. - tiamazolo (metimazolo) - tiamazolo (metimazolo) - 5 mg - thiamazole

Italia - italiano - Ministero della Salute

le vet beheer b.v. - tiamazolo (metimazolo) - tiamazolo (metimazolo) - 2.5 mg - thiamazole

Unione Europea - italiano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. insorti di immunità sono stati dimostrati una settimana dopo il corso di vaccinazione primaria per rinotracheite, calicivirus, chlamydophila felis e componenti di panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unione Europea - italiano - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - prodotti immunologici per felidae, - gatti - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Italia - italiano - Ministero della Salute

medico s.p.a. - elettrocateteri per ventricolo sinistro con sistema di cannulamento del seno coronarico (p.m. tricamerali)

Italia - italiano - Ministero della Salute

fresenius medical care ag & co kgaa - linee arterovenose per dialisi - altre